Anti-IgE as a mast cell-stabilizing therapeutic agent

Journal of Allergy and Clinical Immunology

Volumn 117, Issue 6, 2006, Pages 1203-1212

  Chang, Tse Wen ^a,b   Shiung, Yu Yu ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Allergy; anti IgE; cromones; Fc lunate RI; mast cell stabilizing; mast cells; omalizumab; receptor density; sensitivity

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; BEE VENOM; CALCIUM ION; CROMOGLYCATE DISODIUM; DESLORATADINE; EOTAXIN; FC RECEPTOR; FRACTALKINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 8; KETOTIFEN; LATEX; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPYRAMINE MALEATE; MONOCLONAL ANTIBODY; NEDOCROMIL SODIUM; OLOPATADINE; OMALIZUMAB; RANTES; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIOGENESIS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; B LYMPHOBLAST; BASOPHIL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL ACTIVATION; CELL DIVISION; CELL MIGRATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; CROSS LINKING; CYTOKINE RELEASE; CYTOSKELETON; DENDRITIC CELL; DERMATOPHAGOIDES; DISSOCIATION CONSTANT; DRUG POTENCY; ENDOPLASMIC RETICULUM; EOSINOPHIL; FOOD ALLERGY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATORY CELL; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; MAST CELL; MEDIATOR RELEASE; MONOCYTE; NEUTROPHIL; PEANUT ALLERGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WOUND HEALING;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN E; MAST CELLS;

EID: 33646917507     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.04.005     Document Type: Review

References (94)

1. Storms W., and Kaliner M.A. Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma 42 (2005) 79-89
2. Edwards A.M. The discovery of cromolyn sodium and its effect on research and practice in allergy and immunology. J Allergy Clin Immunol 115 (2005) 885-888
3. van Cauwenberge P., Bachert C., Passalacqua G., Bousquet J., Canonica G.W., Durham S.R., et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55 (2000) 116-134
4. Lanier B.Q. Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE. Ann Allergy Asthma Immunol 90 (2003) 13-15
5. Busse W., and Neaville W. Anti-immunoglobulin E for the treatment of allergic disease. Curr Opin Allergy Clin Immunol 1 (2001) 105-108
6. Babu K.S., Arshad S.H., and Holgate S.T. Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin Biol Ther 1 (2001) 1049-1058
7. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18 (2000) 157-162
8. Boyce J.A. Mast cells: beyond IgE. J Allergy Clin Immunol 111 (2003) 24-33
9. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., and Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23 (2005) 749-786
10. Marshall J.S. Mast-cell responses to pathogens. Nat Rev Immunol 4 (2004) 787-799
11. Stevens R.L., and Austen K.F. Recent advances in the cellular and molecular biology of mast cells. Immunol Today 10 (1989) 381-386
12. Lunderius C., Xiang Z., Nilsson G., and Hellman L. Murine mast cell lines as indicators of early events in mast cell and basophil development. Eur J Immunol 30 (2000) 3396-3402
13. Church M.K., and Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 99 (1997) 155-160
14. Irani A.M., and Schwartz L.B. Human mast cell heterogeneity. Allergy Proc 15 (1994) 303-308
15. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 113 (2004) 395-400
16. Williams C.M., and Galli S.J. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 105 (2000) 847-859
17. Bingham III C.O., and Austen K.F. Mast-cell responses in the development of asthma. J Allergy Clin Immunol 105 suppl (2000) S527-S534
18. Kauffman H.F., Tomee J.F., van de Riet M.A., Timmerman A.J., and Borger P. Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. J Allergy Clin Immunol 105 (2000) 1185-1193
19. Szabo S.J., Sullivan B.M., Peng S.L., and Glimcher L.H. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21 (2003) 713-758
20. Jutel M., Akdis M., Blaser K., and Akdis C.A. Are regulatory T cells the target of venom immunotherapy?. Curr Opin Allergy Clin Immunol 5 (2005) 365-369
21. Oettgen H.C., Martin T.R., Wynshaw-Boris A., Deng C., Drazen J.M., and Leder P. Active anaphylaxis in IgE-deficient mice. Nature 370 (1994) 367-370
22. Miyajima I., Dombrowicz D., Martin T.R., Ravetch J.V., Kinet J.P., and Galli S.J. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest 99 (1997) 901-914
23. Malbec O., Attal J.P., Fridman W.H., and Daeron M. Negative regulation of mast cell proliferation by FcgammaRIIB. Mol Immunol 38 (2002) 1295-1299
24. Kirshenbaum A.S., Kessler S.W., Goff J.P., and Metcalfe D.D. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 146 (1991) 1410-1415
25. Valent P., and Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 52 (1992) 333-423
26. Baghestanian M., Jordan J.H., Kiener H.P., Bevec D., Agis H., Fritsch G., et al. Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2. Int Arch Allergy Immunol 129 (2002) 228-236
27. Fukuzumi T., Waki N., Kanakura Y., Nagoshi J., Hirota S., Yoshikawa K., et al. Differences in irradiation susceptibility and turnover between mucosal and connective tissue-type mast cells of mice. Exp Hematol 18 (1990) 843-847
28. Huang E., Nocka K., Beier D.R., Chu T.Y., Buck J., Lahm H.W., et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63 (1990) 225-233
29. Geissler E.N., Ryan M.A., and Housman D.E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55 (1988) 185-192
30. Austen K.F., and Boyce J.A. Mast cell lineage development and phenotypic regulation. Leuk Res 25 (2001) 511-518
31. Galli S.J., Zsebo K.M., and Geissler E.N. The kit ligand, stem cell factor. Adv Immunol 55 (1994) 1-96
32. Kitaura J., Song J., Tsai M., Asai K., Maeda-Yamamoto M., Mocsai A., et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci U S A 100 (2003) 12911-12916
33. Kawakami T., and Galli S.J. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2 (2002) 773-786
34. Asai K., Kitaura J., Kawakami Y., Yamagata N., Tsai M., Carbone D.P., et al. Regulation of mast cell survival by IgE. Immunity 14 (2001) 791-800
35. Li L., and Krilis S.A. Mast-cell growth and differentiation. Allergy 54 (1999) 306-312
36. Yanagida M., Fukamachi H., Ohgami K., Kuwaki T., Ishii H., Uzumaki H., et al. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86 (1995) 3705-3714
37. Ochi H., Hirani W.M., Yuan Q., Friend D.S., Austen K.F., and Boyce J.A. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190 (1999) 267-280
38. Mekori Y.A., and Metcalfe D.D. Transforming growth factor-beta prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL-3 deprivation. J Immunol 153 (1994) 2194-2203
39. Mekori Y.A., and Metcalfe D.D. Mast cell-T cell interactions. J Allergy Clin Immunol 104 (1999) 517-523
40. Olsson N., Taub D.D., and Nilsson G. Regulation of mast cell migration by T and T cytokines: identification of tumour necrosis factor-alpha and interleukin-4 as mast cell chemotaxins. Scand J Immunol 59 (2004) 267-272
41. Papadopoulos E.J., Fitzhugh D.J., Tkaczyk C., Gilfillan A.M., Sassetti C., Metcalfe D.D., et al. Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur J Immunol 30 (2000) 2355-2361
42. Robinson D.S. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle?. J Allergy Clin Immunol 114 (2004) 58-65
43. Turner H., and Kinet J.P. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 402 (1999) B24-B30
44. Metzger H. The receptor with high affinity for IgE. Immunol Rev 125 (1992) 37-48
45. Siraganian R.P. Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol 15 (2003) 639-646
46. Ott V.L., and Cambier J.C. Activating and inhibitory signaling in mast cells: new opportunities for therapeutic intervention?. J Allergy Clin Immunol 106 (2000) 429-440
47. Machado D.C., Horton D., Harrop R., Peachell P.T., and Helm B.A. Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE. Eur J Immunol 26 (1996) 2972-2980
48. Befus A.D., Mowat C., Gilchrist M., Hu J., Solomon S., and Bateman A. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol 163 (1999) 947-953
49. Castells M.C., Klickstein L.B., Hassani K., Cumplido J.A., Lacouture M.E., Austen K.F., et al. gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol 2 (2001) 436-442
50. Abramson J., Xu R., and Pecht I. An unusual inhibitory receptor-the mast cell function-associated antigen (MAFA). Mol Immunol 38 (2002) 1307-1313
51. Hirasawa N., Santini F., and Beaven M.A. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. J Immunol 154 (1995) 5391-5402
52. Church M.K., and McGill J.I. Human ocular mast cells. Curr Opin Allergy Clin Immunol 2 (2002) 419-422
53. Parikh V., and Singh M. Cardiac mast cell stabilization and cardioprotective effect of ischemic preconditioning in isolated rat heart. J Cardiovasc Pharmacol 31 (1998) 779-785
54. Clark J.D., Lin L.L., Kriz R.W., Ramesha C.S., Sultzman L.A., Lin A.Y., et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 65 (1991) 1043-1051
55. Nabe T., Yamamoto M., Suga M., and Kohno S. Intratracheal dosing with disodium cromoglycate inhibits late asthmatic response by attenuating eicosanoid production in guinea pigs. Eur J Pharmacol 497 (2004) 97-104
56. Supajatura V., Ushio H., Nakao A., Akira S., Okumura K., Ra C., et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109 (2002) 1351-1359
57. Mellor E.A., Austen K.F., and Boyce J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 195 (2002) 583-592
58. Kay A.B., Walsh G.M., Moqbel R., MacDonald A.J., Nagakura T., Carroll M.P., et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol 80 (1987) 1-8
59. Tsicopoulos A., Lassalle P., Joseph M., Tonnel A.B., Thorel T., Dessaint J.P., et al. Effect of disodium cromoglycate on inflammatory cells bearing the Fc epsilon receptor type II (Fc epsilon RII). Int J Immunopharmacol 10 (1988) 227-236
60. Davis F.M., Gossett L.A., Pinkston K.L., Liou R.S., Sun L.K., Kim Y.W., et al. Can anti-IgE be used to treat allergy?. Springer Semin Immunopathol 15 (1993) 51-73
61. Chang T.W., Davis F.M., Sun N.C., Sun C.R., MacGlashan Jr. D.W., and Hamilton R.G. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Biotechnology 8 (1990) 122-126
62. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., et al. Humanization of an antibody directed against IgE. J Immunol 151 (1993) 2623-2632
63. Lanier B.Q., Corren J., Lumry W., Liu J., Fowler-Taylor A., and Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91 (2003) 154-159
64. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
65. Milgrom H. Anti-IgE therapy in children with asthma. Minerva Pediatr 56 (2004) 469-479
66. Holgate S.T., Chuchalin A.G., Hebert J., Lotvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34 (2004) 632-638
67. Berger W., Gupta N., McAlary M., and Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91 (2003) 182-188
68. Nayak A., Casale T., Miller S.D., Condemi J., McAlary M., Fowler-Taylor A., et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 24 (2003) 323-329
69. Kuehr J., Brauburger J., Zielen S., Schauer U., Kamin W., Von Berg A., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109 (2002) 274-280
70. Adelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106 (2000) 253-259
71. Leung D.Y., Shanahan Jr. W.R., Li X.M., and Sampson H.A. New approaches for the treatment of anaphylaxis. Novartis Found Symp 257 (2004) 248-264 76-85
72. Leung D.Y., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993
73. Leynadier F., Doudou O., Gaouar H., Le Gros V., Bourdeix I., Guyomarch-Cocco L., et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 113 (2004) 360-361
74. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117 (2006) 134-140
75. MacGlashan Jr. D., Xia H.Z., Schwartz L.B., and Gong J. IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol 70 (2001) 207-218
76. Saini S.S., Klion A.D., Holland S.M., Hamilton R.G., Bochner B.S., and Macglashan Jr. D.W. The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol 106 (2000) 514-520
77. MacGlashan Jr. D., McKenzie-White J., Chichester K., Bochner B.S., Davis F.M., Schroeder J.T., et al. In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 91 (1998) 1633-1643
78. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997) 1438-1445
79. Malveaux F.J., Conroy M.C., Adkinson Jr. N.F., and Lichtenstein L.M. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 62 (1978) 176-181
80. Hashiguchi S., Nakashima T., Nitani A., Yoshihara T., Yoshinaga K., Ito Y., et al. Human Fc epsilon RIalpha-specific human single-chain Fv (scFv) antibody with antagonistic activity toward IgE/Fc epsilon RIalpha-binding. J Biochem (Tokyo) 133 (2003) 43-49
81. Macglashan Jr. D. IgE and Fcε{lunate}RI regulation. Ann N Y Acad Sci 1050 (2005) 73-88
82. Borkowski T.A., Jouvin M.H., Lin S.Y., and Kinet J.P. Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol 167 (2001) 1290-1296
83. Wedemeyer J., and Galli S.J. Mast cells and basophils in acquired immunity. Br Med Bull 56 (2000) 936-955
84. Wedemeyer J., Tsai M., and Galli S.J. Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol 12 (2000) 624-631
85. Saini S.S., MacGlashan Jr. D.W., Sterbinsky S.A., Togias A., Adelman D.C., Lichtenstein L.M., et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162 (1999) 5624-5630
86. Holgate S.T., Djukanovic R., Casale T., and Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 35 (2005) 408-416
87. Wang Y.H., Tache Y., Harris A.G., Kreutner W., Daly A.F., and Wei J.Y. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 60 (2005) 117-124
88. McGill J.I. A review of the use of olopatadine in allergic conjunctivitis. Int Ophthalmol 25 (2004) 171-179
89. Nagler A., Segal V., Slavin S., and Levi-Schaffer F. Ketotifen therapy in chronic graft-versus-host disease (cGVHD): effect on mast cells and fibroblasts. Clin Exp Immunol 100 (1995) 529-535
90. Tabuchi Y., Kawarabayashi K., and Furuhama K. Inhibitory effect of DS-4574, a peptidoleukotriene antagonist with mast cell stabilizing action, on compound 48/80-induced gastric mucosal lesions in rats. Agents Actions 41 (1994) 21-24
91. He S., Aslam A., Gaca M.D., He Y., Buckley M.G., Hollenberg M.D., et al. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release. J Pharmacol Exp Ther 309 (2004) 119-126
92. He S., Gaca M.D., McEuen A.R., and Walls A.F. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells. J Pharmacol Exp Ther 291 (1999) 517-523
93. Blank U., and Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 25 (2004) 266-273
94. Zhu D., Kepley C.L., Zhang K., Terada T., Yamada T., and Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 11 (2005) 446-449